NXD — Nucleic Acid Amplification, Novel Influenza A Virus, A/H5 (Asian Lineage) Rna Class II

FDA Device Classification

FDA product code NXD covers "Nucleic Acid Amplification, Novel Influenza A Virus, A/H5 (Asian Lineage) Rna", a Class II medical device regulated under 21 CFR 866.3332. Submissions are reviewed by the Microbiology panel. At least 3 recent 510(k) clearances have been granted under this product code.

Classification Details

Product Code
NXD
Device Class
Class II
Regulation Number
866.3332
Submission Type
Review Panel
MI
Medical Specialty
Microbiology
Implant
No

Definition

Novel influenza a virus reagents are used in nucleic acid amplification tests to directly detect and differentiate novel influenza a virus specific rna gene segments in human respiratory specimens or viral cultures. Detection and differentiation of specific rna gene segments aids in the diagnosis of influenza caused by novel influenza a viruses in patients with clinical and epidemiological risk of infection with these viruses. They also aid in the presumptive identification of specific novel influenza a viruses and provide epidemiological information on influenza. These reagents are primers and probes, along with a specific novel influenza virus control.

Recent 510(k) Clearances

K-NumberApplicantDevice NameDate
K100287u.s. army medical material development commandJBAIDS INFLUENZA A/H5 DETECTION KIT, MODEL JRPD-ASY-0136July 6, 2010
K080570centers for disease control and preventionCDC HUMAN INFLUENZA VIRUS REAL-TIME RT- PCR DETECTION AND CHARACTERIZATION PANELSeptember 30, 2008
DEN060008centers for disease control and preventionINFLUENZA A/H5 (ASIAN LINEAGE) VIRUS REAL-TIME RT-PCR PRIMER AND PROBE SETFebruary 3, 2006